Roles of Prostaglandin I <sub>2</sub> and Thromboxane A <sub>2</sub> in Cardiac Ischemia-Reperfusion Injury

DOI Web Site 被引用文献14件
  • Chun-Yang Xiao
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Akiyoshi Hara
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Koh-ichi Yuhki
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Takayuki Fujino
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Hong Ma
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Yuji Okada
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Osamu Takahata
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Takehiro Yamada
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Takahiko Murata
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Shuh Narumiya
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.
  • Fumitaka Ushikubi
    From the Department of Pharmacology, Asahikawa Medical College, Asahikawa (C-Y.X., A.H., K.Y., T.F., H.M., Y.O., O.T., T.Y., F.U.), and the Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto (T.M., S.N.), Japan.

書誌事項

タイトル別名
  • A Study Using Mice Lacking Their Respective Receptors

抄録

<jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Background</jats:italic> </jats:bold> </jats:italic> </jats:bold> Prostaglandin (PG) I <jats:sub>2</jats:sub> and thromboxane (TX) A <jats:sub>2</jats:sub> , the most common prostanoids in the cardiovascular system, are produced abundantly during cardiac ischemia/reperfusion (I/R); their roles in I/R injury, however, remain undetermined. We intended to clarify these roles of PGI <jats:sub>2</jats:sub> and TXA <jats:sub>2</jats:sub> using mice lacking the PGI <jats:sub>2</jats:sub> receptor, IP <jats:sup>−/−</jats:sup> mice, or the TXA <jats:sub>2</jats:sub> receptor, TP <jats:sup>−/−</jats:sup> mice. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Methods and Results</jats:italic> </jats:bold> </jats:italic> </jats:bold> The left anterior descending coronary artery was occluded for 1 hour and then reperfused for 24 hours. The size of myocardial infarct in IP <jats:sup>−/−</jats:sup> mice was significantly larger than that in wild-type mice, although the size of the area at risk was similar between the 2 groups of mice. In contrast, there was no such difference between TP <jats:sup>−/−</jats:sup> and wild-type mice. To further determine whether PGI <jats:sub>2</jats:sub> and TXA <jats:sub>2</jats:sub> act directly on the cardiac tissue or indirectly through their action on blood constituents, we perfused excised heart according to the Langendorff technique. The isolated heart was then subjected to global ischemia followed by reperfusion. In IP <jats:sup>−/−</jats:sup> mice, developed tension and coronary flow rate during reperfusion were significantly lower and release of creatine kinase was significantly higher than those in wild-type mice. There were no such differences, however, between TP <jats:sup>−/−</jats:sup> and wild-type mice. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Conclusions</jats:italic> </jats:bold> </jats:italic> </jats:bold> PGI <jats:sub>2</jats:sub> , which was produced endogenously during cardiac I/R, exerts a protective effect on cardiomyocytes independent of its effects on platelets and neutrophils. In contrast, TXA <jats:sub>2</jats:sub> has little role in the cardiac I/R injury. </jats:p>

収録刊行物

  • Circulation

    Circulation 104 (18), 2210-2215, 2001-10-30

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ